Using a relatively young theory, a team of mathematicians has started to answer questions whose roots lie at the very ...
Objective Organ damage is a key determinant of poor prognosis and increased mortality in systemic lupus erythematosus (SLE).
The FDA has rejected a biologics license application for apitegromab to treat spinal muscular atrophy, according to manufacturer Scholar Rock.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback